Medication adherence, depression and disease activity among patients with systemic lupus erythematosus

Abstract

Introduction Medication non-adherence is an important cause of treatment failure among patients with systemic lupus erythematosus (SLE). Depression is a common neuropsychiatric disorder associated with SLE. The aims of this study are to assess the prevalence of both medication non-adherence and depressed mood among Saudi patients with SLE by using validated tools and to explore the impact of both depressive symptoms and disease activity on medication non-adherence. Methods A cross-sectional study was conducted in outpatients with SLE. Medication non-adherence was assessed by using the Morisky Medication Adherence Scale, and the severity of depressed mood was evaluated with the Beck's Depression Inventory. Disease activity was measured using the SLE Disease Activity Index (SLEDAI). Multiple logistic regression models were used to identify the multivariate predictors of medication non-adherence. Results Out of 140 patients, 134 (95.7%) were females with a mean (±SD) age of 35.6 (±11.3) years and a disease duration of 8.8 (±6.7) years. Medication non-adherence and depressed mood were detected in 62.1% and 35% of the patients, respectively. A moderate or severe depressed mood was significantly associated with medication non-adherence ( p = 0.04). There was a significant correlation between disease activity and the severity of depressed mood ( r = 0.31, p = 0.003). Disease activity did not correlate with medication non-adherence. Logistic regression demonstrated that moderate-to-severe depressed mood increased the probability of medication non-adherence (OR 2.62; 1.02-6.71). Conclusion Medication non-adherence and depressive symptoms are highly prevalent among Saudi SLE patients. Routine screening could facilitate the early detection and management of depression and medication adherence.

Risk of benign paroxysmal positional vertigo in patients with depressive disorders: a nationwide population-based cohort study

“…Consistent with the studies mentioned above, we found that SLE is a risk factor for BPPV among depressive cohort (table 4) but not for all the participants (table 3) in this study. Based on the previous studies, several results of the studies could provide the evidence revealing that the comorbidities with depressive disorder and SLE would result in the exacerbation of the SLE disease activities, no matter the possible explanations were psychological or behavioural issues such as lack of insight and poor anti-inflammatory drug compliance 48–50. The evidence indicated that the severity of inflammatory processes on the differences between the patients with depressive disorder alone and the depressive patients comorbid with SLE.…”

Systemic lupus erythematosus: what do Chinese patients and general practitioners know?

“…The challenges can include favouring disease remission, limiting the use of glucocorticoids, managing fertility and pregnancy, managing comorbidities and so on [2] . Besides, current evidence suggests that the percentage of nonadherent patients ranged from 37% to 75%, which have a remarkable correlation with depression, low education level and polypharmacy [3][4][5][6][7] . Interventions to improve adherence and management of patients have become an urgent requirement.…”

Renal transplantation for lupus nephritis: non-adherence and graft survival

“…In addition, the retrospective nature of the study did not allow us to screen accurately for depression, a factor known to be associated with non-adherence in the general lupus population 18 . Finally, despite one of the longest recorded follow up periods exceeding 422 patient-years we only had 12 patients with graft rejection or failure, which may have impacted on identifying smaller potential associations with the other variables included in this study.…”